Lymphocyte surface marker expression in rheumatic diseases: evidence for prior activation of lymphocytes in vivo

Malcolm D Smith, Peter J Roberts-Thomson

Abstract

Expression of major histocompatibility complex (MHC) class II and other lymphocyte activation markers on peripheral blood and synovial fluid T lymphocytes from patients with rheumatoid arthritis (RA), psoriatic arthritis, and Reiter's syndrome were measured and the mean fluorescence intensities of these antigens were assessed. Increased expression of MHC class II antigens of synovial fluid T lymphocytes is not unique to RA, though it is quantitatively greater on RA synovial fluid T cells. There was less expression of other lymphocyte activation markers (4F2, transferrin receptor) and a marked discordance between the expression of these markers and the interleukin 2 receptor (IL2r). Synovial fluid T lymphocytes contain a subpopulation of larger cells expressing MHC class II and other lymphocyte activation antigens with the exception of the IL2r. Mean fluorescence intensity of CD3 and CD4 antigens on synovial fluid T lymphocytes was decreased in all three patient groups, suggesting prior in vivo exposure of synovial fluid T lymphocytes to an unknown antigen.

Rheumatoid arthritis (RA) is a chronic inflammatory condition characterised by a marked mononuclear cell infiltrate in synovial tissue and synovial fluid, with T lymphocytes being prominent. Persistent immunological activity of these T lymphocytes in response to an unknown antigen is thought to be a major reason for the immunohistological changes seen in RA synovial tissue. Despite this attractive hypothesis there has been controversy about the phenotypic and functional characteristics of T lymphocytes in RA peripheral blood and, particularly, synovial fluid. Although most studies agree about the predominance of CD4 positive T cells in peripheral blood and CD8 positive T cells in synovial fluid of patients with RA,¹⁻¹¹ there is disagreement about the predominant T cell subset in RA synovial tissue.^{2, 11-15} Greater differences can be found in published studies reporting on lymphocyte activation markers (including major histocompatibility complex (MHC) class II antigens, interleukin 2 receptor (IL2r), transferrin receptor) expressed on RA peripheral blood and synovial fluid lymphocytes. Some studies have reported increased expression of IL2r and transferrin receptor on RA peripheral blood^{15, 16} and synovial fluid^{15, 17, 18} T lymphocytes, whereas other studies have found little or no increased expression of these markers on peripheral blood^{3, 11, 17} or synovial

fluid T lymphocytes.^{3, 11} Most studies agree that there is a considerable discordance between the markedly increased MHC class II expression and the marginal increase in IL2r expression on RA synovial fluid T cells,^{3, 11, 15, 17, 18} in contrast with the coexpression of these antigens on T lymphocytes stimulated in vitro.¹⁷⁻¹⁹

Similar controversy exists about the functional state of these T cells, particularly relating to the presence of IL2 in RA synovial fluid and the ability of RA peripheral blood and synovial fluid T lymphocytes to produce IL2, express IL2r, and respond to exogenous IL2.²⁰⁻²⁵

Increased size of T lymphocytes in RA synovial fluid has been reported, similar to that of in vitro stimulated peripheral blood lymphocytes from normal subjects, suggesting that the T lymphocytes are 'activated'.^{6, 15, 18} Recent studies on RA synovial fluid²³ and synovial tissue²⁶ T lymphocytes have shown downregulation of the CD3 antigen and expression of late 'activation' markers^{26, 27} on these cells, suggesting prior activation of intra-articular T cells in vivo.

There have been few publications examining the phenotypic or functional characteristics of T lymphocytes in other inflammatory arthritides.^{11, 28, 29} Patients with inflammatory arthritides have sometimes been included in a control group for comparison with the findings in patients with RA. Therefore the specificity of the T lymphocyte phenotypic and functional characteristics for RA is unknown. We report our findings on the phenotypic characteristics of peripheral blood and synovial fluid T lymphocytes in a large group of patients with RA as well as a group of patients with psoriatic arthritis and Reiter's syndrome. The functional characteristics of the T cells in these patient groups are reported elsewhere.³⁰

Patients and methods

PATIENTS AND CONTROLS

Table 1 presents details of the patients studied. All patients with RA had classical or definite RA³¹ and all patients with psoriatic arthritis had an asymmetrical polyarthritis with a persistently negative rheumatoid factor and a personal or family history of psoriasis. All patients with Reiter's syndrome conformed to the American Rheumatism Association criteria for definite Reiter's syndrome³² and had persistently negative rheumatoid factor tests. All patients with crystal arthritis had a history of acute monoarthritis with a synovial fluid cell content consisting mainly of neutrophils containing intracellular monosodium urate or calcium

Department of Clinical Immunology, Flinders Medical Centre, Adelaide, South Australia
M D Smith
P J Roberts-Thomson

Correspondence to:
Dr Malcolm D Smith,
Arthritis Unit,
Massachusetts General
Hospital, Boston,
Massachusetts, USA 02114.

Accepted for publication
10 April 1989

Table 1: Clinical and laboratory indices for the patient groups studied

	RA* blood	RA SF*	PA SF*	RS SF*	CA SF*	Control blood
Number	55	44	10	15	6	55
Mean age (years)	65.8	64.06	43	30	66	60.4
Sex (M:F)	23:32	18:26	7:3	13:2	5:1	23:32
Disease duration (years)	6.6	6.94	4.6	2.2	3.8	—
NSAIDs*	54	38	6	5	6	20†
SAARDs*						
Gold	8	5	1	0	0	—
D-Penicillamine	5	5	0	0	0	—
Sulphasalazine	3	0	0	0	0	—
Methotrexate	2	2	1	0	0	—
None	37	32	8	15	6	55
Steroids	3	3	0	0	0	0
CRP* (mg/l)	51.7	34.6	20	33.8	35	<6‡
RF* (IU/ml)	1608	1158	<60	<60	<60	<60‡
IgG (g/l)	13.08	9.54	5.55	6.68	8.53	7–19‡
IgM (g/l)	1.99	0.99	0.83	0.57	1.16	0.55–2.20‡
IgA (g/l)	3.38	2.64	0.83	1.35	3.27	0.50–4.00‡

*RA=rheumatoid arthritis; SF=synovial fluid; PA=psoriatic arthritis; RS=Reiter's syndrome; CA=crystal arthritis; NSAIDs=non-steroidal anti-inflammatory drugs; SAARDs=slow acting antirheumatic drugs; CRP=C reactive protein; RF=rheumatoid factor. †These control subjects were taking NSAIDs for non-inflammatory conditions. ‡Normal ranges.

pyrophosphate crystals on polarised microscopic examination.

Activity of articular disease was defined by a combination of duration of morning stiffness (>30 minutes), articular index, and laboratory parameters (C reactive protein, erythrocyte sedimentation rate, and synovial fluid white cell count).

Details of age, sex, disease duration, and drugs taken were recorded for all patients studied. Serum and synovial fluid from all patients were analysed for C reactive protein, rheumatoid factor, and immunoglobulin concentrations by rate nephelometry (Beckman Instruments, Brea, Ca). The control group were healthy subjects without any known inflammatory condition at the time of study matched for age and sex with the group with RA.

PREPARATION OF MONONUCLEAR CELL SUSPENSIONS

Most synovial effusions had been present for less than three months and were obtained by percutaneous arthrocentesis of inflamed knee joints. Synovial fluid was processed immediately as previously described.^{7, 33} Mononuclear suspensions from peripheral blood were prepared by Ficoll-Hypaque (Nyegaard) gradient centrifugation.⁷

MONOCLONAL LABELLING TECHNIQUE

Standard indirect immunofluorescence was used with successive 30 minute incubations at 4°C of 10 million mononuclear cells (in 100 µl phosphate buffered saline containing 0.02% azide) with a monoclonal antibody followed by pooled human serum and fluorescein conjugated goat antimouse antibody.⁷ Cells were fixed in phosphate buffered saline containing 1% para-formaldehyde and stored in the dark at 4°C until analysed. Positive (FMC16), negative (X63), and monocyte (FMC33) controls were included in each analysis. Table 2 lists the monoclonal antibodies used.

For dual immunofluorescence studies, directly conjugated antibodies (HLA-DR-fluorescein isothiocyanate (FITC), IL2r-phycoerythrin, IL2r-FITC, Leu2a-phycoerythrin, Leu3a-phycoerythrin; Becton Dickinson) were used if available and both direct labelled antibodies were incubated simultaneously.³³ When direct labelled antibodies were unavailable (4F2, transferrin receptor, FMC56) an indirect immunofluorescent step was followed by incubation with a phycoerythrin labelled monoclonal antibody. Previous studies have shown no cross reaction between the two fluorochromes,³³ and cells were also single labelled with each antibody (FITC and phycoerythrin labelled) to exclude any cross reaction.

Table 2: Monoclonal antibodies used in indirect immunofluorescence

Monoclonal antibody	Immunoglobulin class	Description
FMC16	IgG2a/K	β ₂ Microglobulin (positive control)
X63	IgG1/K	Mouse myeloma antibody (negative control)
FMC33(CD14)	IgG1/K	Monocyte/macrophage cells ³⁴
OKT4(CD4)*	IgG2b	Helper/inducer cell
OKT8(CD8)*	IgG2	Suppressor/cytotoxic cell
OKT3(CD3)*	IgG2a	Pan T cell
Leu1(CD5)†	IgG2a/K	Pan T cell, subset of B cells
B7/21	IgG1/K	MHC class II antigen (DP) ³⁵
Leu10†	IgG2/K	MHC class II antigen (DQ)
HLA-DR†	IgG2a/K	MHC class II antigen (DR)
FMC14	IgG1/K	MHC class II (DP, DQ, DR) ³⁶
FMC56 (CD9)	IgG1/K	Mid/late activation marker ³⁷
4F2	IgG2a/K	Early activation marker ³⁸
OKT9*	IgG1	Transferrin receptor, mid activation marker
IL2r‡ (CD25)†	IgG1/K	Early activation marker
SMIG‡	F(ab) ₂	B cell
Leu7†	IgM/K	CD8 and NK cells
Leu11b†	IgM/K	CD8 and NK cells

*Orthodiagnostics Laboratories.

†Becton-Dickinson Laboratories.

‡Silenus Laboratories.

§IL2r=interleukin 2 receptor; MHC=major histocompatibility complex; NK=natural killer.

Fluorescence was analysed on a Becton Dickinson FACS IV analyser using a mercury arc lamp for excitation of both fluorescein and phycoerythrin at a wavelength of 484 nm. Fluorescence emission was detected by selective collecting through photomultipliers at 530 (fluorescein) and 595 (phycoerythrin) nm. Analysis of 10 thousand cells was performed with a Becton Dickinson Consort 30 computer system. Fluorescence analysis was carried out by gating the lymphocytes and delineating positive and negative markers using the positive and negative controls included in each experiment. Monocyte contamination of the gated population was less than 3% as determined by FMC33 fluorescence. Antigen density was indirectly assessed by measuring the mean fluorescence intensity of the analysed cells for each monoclonal antibody.²³ Volume analysis was performed by gating for strongly positive cell populations on fluorescence histograms and analysing the volume distribution of this population.¹⁸

PERIPHERAL BLOOD LYMPHOCYTE STIMULATION
Peripheral blood mononuclear cells from control subjects were prepared as above and resuspended in RPMI containing 10% heat inactivated fetal calf serum (Gibco) at 1 million viable cells (trypan blue exclusion) per ml. Cells were cultured in tissue culture flasks in a 37°C, 5% CO₂ incubator for three to seven days in the presence of OKT3 (Orthodiagnostics) antibody at a final concentration of 2.5 ng/ml. At the time of harvesting cells were washed extensively in phosphate buffered saline with azide, adjusted to a concentration of 10 million viable cells (trypan blue exclusion)/ml and labelled as above. Tritiated thymidine (Amersham) uptake was assessed on each day of harvesting to ensure that mitogenic stimulation was adequate.

STATISTICAL ANALYSIS

An SPSSX computer package was used for statistical analysis. A *t* test, one way, and multiple analysis of variance and Pearson correlations (corrected for number of comparisons) were performed. Statistical significance was accepted at the 5% level.

Results

IMMUNOFLUORESCENCE STUDIES

Single and dual fluorescence studies on CD3 monoclonal antibody stimulated lymphocytes confirmed the early expression of IL2r and 4F2 antigens, which persisted for the seven days of culture. Transferrin receptor was expressed after these two antigens and declined to low levels by the seventh day of culture. MHC class II expression appeared later and did not peak until the seventh day of culture (results not shown). Both CD4 (58% positive) and CD8 (65% positive) T lymphocytes expressed HLA-DR antigens after mitogenic stimulation and there was concordance between expression of MHC class II, 4F2, IL2r, and transferrin receptor on these lymphoblasts (results not shown).

There were more CD3 positive cells in synovial fluid samples than in peripheral blood, irrespective of diagnosis. An increase in CD4 positive cells and a decrease in CD8 positive cells was seen in RA peripheral blood and in synovial fluid from patients with psoriatic arthritis, Reiter's syndrome, and crystal arthritis, while the opposite was seen in RA synovial fluid (table 3). A small but significant increase in MHC class II expression was seen on RA peripheral blood lymphocytes ($p<0.005$) and a much greater increase on RA synovial fluid lymphocytes ($p<0.005$) than on control peripheral blood lymphocytes. While most of the RA peripheral blood CD4 lymphocytes were MHC class II negative ($p<0.005$ compared with CD4+DR+ cells), almost half the CD8 peripheral blood lymphocytes expressed the HLA-DR antigen (table 4). In contrast, there were more CD4+DR+ and CD8+DR+ in RA synovial fluid than in RA peripheral blood ($p<0.005$), with the predominant lymphocyte subset expressing MHC class II antigen being the CD8 positive cell. There was little coexpression of IL2r with any of the other antigens on the RA peripheral blood or synovial fluid cells (table 4) and there was no increased expression of IL2r, transferrin receptor, or FMC56 on RA peripheral blood or synovial fluid lymphocytes (table 3).

A statistically significant increase in MHC class II expression on synovial fluid lymphocytes from patients with psoriatic arthritis, Reiter's

Table 3: Lymphocyte surface markers on peripheral blood lymphocytes from patients with rheumatoid arthritis and control subjects, and on synovial fluid lymphocytes from patients with rheumatoid arthritis, psoriatic arthritis, Reiter's syndrome, and crystal arthritis. Results are expressed as mean percentage positive cells (SEM)

Monoclonal antibody	Control blood	RA ∇ blood	RA SF ∇	PA ∇ SF	RS ∇ SF	CA ∇ SF
CD3	76.2 (1.1)	73.0 (4.4)	82.0 (1.4)** ∇	78.4 (5.2)**	87.5 (2.1)**	89.1 (2.2)**
CD4	48.2 (2.6)	58.4 (3.1)	42.5 (2.8) ∇	55.1 (4.2) ∇	59.0 (4.8) ∇	66.2 (3.4) ∇
CD8	41.0 (1.4)	29.3 (1.1)	39.7 (2.4)** ∇	27.8 (4.4) ∇	24.5 (3.6) ∇	20.4 (0.6) ∇
MHC class II	8.8 (0.6)	14.8 (0.8)**	51.8 (3.6)** ∇	33.6 (5.2)**	34.4 (2.6)**	28.2 (1.4)**
FMC56	8.1 (0.5)	14.6 (0.8)**	12.4 (2.0)	12.8 (5.2)	4.6 (1.2)	5.8 (1.0)
4F2	4.2 (0.4)	7.6 (0.7)*	12.5 (4.4)	18.6 (6.4)	10.0 (6.2)	8.2 (4.4)
Transferrin receptor	3.1 (0.3)	4.8 (0.5)	5.1 (0.8)	4.6 (0.4)	0.6 (0.4)	1.6 (0.2)
IL2r	3.0 (0.2)	4.8 (0.6)	3.6 (1.1)	7.8 (2.8)	4.2 (0.8)	3.8 (0.4)
SMIG	8.9 (3.1)	14.4 (1.4)*	7.4 (1.2)	4.6 (0.6)	2.2 (0.2)	3.0 (1.4)
Leu7	21.1 (4.8)	29.4 (3.6)	25.6 (5.2)	23.4 (12.4)	11.2 (3.6)	ND
Leu11b	12.3 (1.8)	17.6 (2.4)	7.4 (4.2)	29.6 (16.6)	5.2 (1.0)	ND

* $p<0.05$ compared with control peripheral blood lymphocytes.

** $p<0.005$ compared with control peripheral blood lymphocytes.

∇ $p<0.05$ compared with paired RA peripheral blood lymphocytes.

∇ $p<0.005$ compared with paired RA peripheral blood lymphocytes.

∇ $p<0.005$ compared with RA synovial fluid lymphocytes.

∇ RA=rheumatoid arthritis; SF=synovial fluid; PA=psoriatic arthritis; RS=Reiter's syndrome; CA=crystal arthritis.

syndrome, and crystal arthritis was seen ($p < 0.005$), though less than that seen on RA synovial fluid lymphocytes (table 3). Both CD4 and CD8 cells expressed MHC class II antigens in these synovial fluid samples (table 4), though CD4+DR- T lymphocytes predominated ($p < 0.005$). Most of these MHC class II antigen positive T cells did not express IL2r (table 4).

Small increases in cells expressing Leu7, Leu11, and B cell (SMIG) antigens were seen in RA peripheral blood, which did not reach statistical significance.

Mean fluorescence intensities for CD3, CD4, IL2r, 4F2, and MHC class II antigens on RA peripheral blood lymphocytes were lower than those seen on control peripheral blood lymphocytes, while mean fluorescence intensities for CD3, CD4, and FMC56 were lower on both RA and non-RA synovial fluid lymphocytes (except for CD4 on psoriatic arthritis lymphocytes) (table 5). None of these changes reached statistical significance, but the reduction in CD3 and CD4 mean fluorescence intensity was greater than that seen on lymphocytes stimulated by CD3 antibody (day 3 lymphoblasts, table 5), where downregulation of these antigens is known to occur.¹⁹ In contrast, there was no increase in mean fluorescence intensity of IL2r, 4F2, or transferrin receptor on synovial fluid lymphocytes compared with the upregulation of these antigens on the in vitro stimulated lymphocytes (table 5).

VOLUME ANALYSIS OF LYMPHOCYTES IN PERIPHERAL BLOOD AND SYNOVIAL FLUID

T lymphocytes selected by gating for strong fluorescence with OKT3 (also independently with Leu1) showed a bimodal scatter of volumes in peripheral blood and especially synovial fluid

from patients with RA (fig 1a). Similar results were obtained when synovial fluid from patients with psoriatic arthritis and Reiter's syndrome was studied, showing that this was not unique to RA synovial fluid (results not shown). The larger T cell population in synovial fluid contained both CD4 and CD8 cells (fig 1b).

Figure 1: Volume analysis of peripheral blood lymphocytes (PBLs) and synovial fluid lymphocytes from patients with rheumatoid arthritis (RA). (a) CD3 positive cells in RA peripheral blood and synovial fluid; (b) CD3, CD4, and CD8 cells in RA synovial fluid.

Table 4: Dual immunofluorescence labelling of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis, psoriatic arthritis, and Reiter's syndrome. Results are expressed as mean percentage positive cells (SEM)

	RA† blood	RA SF†	PA† SF	RS† SF
CD4+DR+	8.2 (0.8)	22.6 (2.4)*	16.4 (2.2)	14.8 (1.4)
CD4+DR-	47.6 (3.4)	21.4 (3.2)	37.8 (4.6)†	36.4 (3.2)†
CD8+DR+	10.4 (1.4)	36.2 (6.4)*	16.8 (3.4)	14.4 (2.2)
CD8+DR-	11.2 (1.0)	8.6 (1.0)	14.6 (2.6)	12.4 (1.6)
DR+IL2r+	4.6 (0.8)	8.4 (0.6)	4.2 (1.2)	4.8 (0.4)
DR+IL2r-	13.4 (1.4)	46.8 (6.2)	34.4 (6.8)	33.2 (2.8)
4F2+IL2r+	0.4 (0.2)	1.6 (0.4)	1.6 (0.4)	0.6 (0.2)
4F2+IL2r-	6.4 (1.2)	13.3 (5.4)	14.6 (6.2)	4.1 (2.4)
Tr+IL2r+	0.8 (0.2)	2.3 (1.2)	0.6 (0.2)	0.8 (0.4)
Tr+IL2r-	4.9 (1.6)	11.6 (4.6)	4.2 (1.2)	4.4 (1.4)

* $p < 0.005$ compared with paired RA peripheral blood lymphocytes.

† $p < 0.05$ compared with RA synovial fluid lymphocytes.

‡RA=rheumatoid arthritis; SF=synovial fluid; PA=psoriatic arthritis; RS=Reiter's syndrome.

Table 5: Mean fluorescence intensity for T lymphocyte surface antigens in rheumatoid arthritis, psoriatic arthritis, and Reiter's syndrome peripheral blood and synovial fluid as well as CD3 antibody stimulated control peripheral blood lymphocytes. Values are means (SD)

Patient group	CD3	CD4	CD8	IL2r	FMC56	4F2	Tr*	MHC class II
RA* blood	124.34 (82.7)	72.58 (41.6)	204.6 (103.7)	47.3 (23.6)	174.3 (134)	69.6 (34.3)	74.5 (41)	135 (94)
RA SF*	114.1 (68.4)	94.8 (50.5)	242.5 (148)	64.8 (31.4)	95.7 (57)	92.7 (57)	87.1 (74)	197 (84.6)
PA* blood	207.1 (58.6)	102.6 (64)	187.4 (101)	42.4 (24)	144.1 (54)	56.8 (37)	76 (76)	208 (103)
PA SF	159 (32)	123 (77.6)	228 (163.5)	78.1 (50.5)	82.4 (43.8)	99.8 (40.7)	75.4 (64)	133 (44.7)
RS* blood	254 (85.8)	95.6 (50.5)	189.7 (100)	80.9 (30.2)	203.3 (107)	99.1 (44.7)	91 (56)	168 (97)
RS SF	129.6 (47.4)	95.7 (50.1)	196.2 (96.7)	66.2 (25.6)	68.2 (23)	76 (35.3)	65.8 (35)	179 (139)
Control blood	193.7 (66)	106.6 (50.7)	223.1 (106)	69.1 (60.7)	130.2 (74)	82 (50.7)	76.3 (54)	202 (110)
Day 3 lymphoblasts	178.5 (54.4)	127.8 (48.6)	652.4 (126.4)	345.1 (176)	120.4 (66)	307.8 (163)	186.3 (60)	228 (110)

*RA=rheumatoid arthritis; SF=synovial fluid; PA=psoriatic arthritis; RS=Reiter's syndrome; Tr=transferrin receptor.

This larger cell population also expressed most of the MHC class II antigens (fig 2a), as well as other lymphocyte activation markers (fig 2b), with the exception of IL2r, which was minimally expressed on both the small and large T cell populations in synovial fluid. A similar volume distribution of T lymphocytes expressing MHC class II and lymphocyte activation markers (4F2) was seen when peripheral blood lymphocytes were stimulated *in vitro* with CD3 antibodies, with the exception that the IL2r was also expressed on the larger T cell population (fig 3).

Figure 2: Volume analysis of rheumatoid arthritis (RA) synovial fluid lymphocytes (a) Volume distribution of cells expressing CD3 and MHC class II antigens (HLA-DP, DQ, and DR); (b) volume distribution of cells expressing lymphocyte activation markers.

Figure 3: Volume analysis of control peripheral blood lymphocytes stimulated *in vitro* with CD3 antibodies (OKT3). (a) Volume distribution of T cells (Leu1) and MHC class II antigens in stimulated and unstimulated cells; (b) volume distribution of IL2r and 4F2 antigens in stimulated and unstimulated cells.

CORRELATION BETWEEN LYMPHOCYTE SURFACE MARKERS AND CLINICAL AND LABORATORY INDICES

There was no correlation between any of the clinical indices of disease activity and the lymphocyte markers detected on peripheral blood or synovial fluid T lymphocytes of any of the patient groups studied. There was a direct correlation between MHC class II antigen expression on RA peripheral blood and synovial fluid lymphocytes and IgG ($p < 0.05$, 0.005), IgM ($p < 0.05$, 0.005), and rheumatoid factor ($p < 0.05$, 0.05) levels in serum and synovial fluid respectively. There was also a significant direct correlation between rheumatoid factor levels and CD8 positive cells ($p < 0.05$) and an inverse correlation with CD4 positive cells ($p < 0.05$) in RA synovial fluid. There were no significant correlations between cell surface marker expression and any of the clinical or laboratory indices of disease activity in the group of patients with seronegative arthritis.

Discussion

Recent publications have shown the prominence of T lymphocyte populations in synovial fluid and peripheral blood of patients with RA, and it has been proposed that this cell is important in the chronic inflammatory process seen in RA synovial tissue.^{12 14 15 23 26} *In vitro* models of T cell activation have defined the normal pathways of T cell proliferation and differentiation, involving a sequential process of IL2 production and IL2r upregulation, together with down-regulation of the T cell receptor, followed by reversal of these changes in the absence of continuing antigen exposure.^{19 39 40}

Although there is general agreement about the T cell subsets in RA peripheral blood (excess of CD4 and deficiency of suppressor CD8 cells)¹⁰ and synovial fluid (excess of cytotoxic CD8 cell),⁴¹ there is disagreement about the expression of antigens indicating an activated lymphocyte state. Although most studies agree that there is a modest increase in MHC class II antigens on RA peripheral blood lymphocytes²⁻⁸ and a greater increase in expression on RA synovial fluid lymphocytes,^{2 5-7 11 17 18 42} there is considerable disagreement about expression of other T lymphocyte activation markers (IL2r, transferrin receptor).^{3 11 15-18} In addition, there is considerable conflict in published work about the presence of IL2 in RA synovial fluid and the production of IL2 and expression of IL2r (high and low affinity) on RA peripheral blood and synovial fluid T lymphocytes.^{20-25 43 44}

In this study we have shown, like other investigators, that CD4 positive T cells predominate in RA peripheral blood, while CD8 positive T cells predominate in RA synovial fluid. The major T lymphocyte subset in RA synovial fluid expressing MHC class II antigens was the CD8 positive T cell, while a minority of both CD4 and CD8 T cell subsets in RA peripheral blood expressed MHC class II antigens.

In vitro studies of T lymphocyte proliferation

have shown an increase in size of T cells stimulated with plant lectins, with coexpression of MHC class II antigens and other lymphocyte activation markers (IL2r, transferrin receptor, 4F2), as well as downregulation of the T cell receptor and upregulation of the IL2r.^{19 39 40 45} Whereas RA synovial fluid (and to a lesser extent peripheral blood) T lymphocytes show a modest decrease in mean fluorescence intensity of CD3 and CD4 antigens (compared with control peripheral blood lymphocytes), suggesting downregulation of these antigens, there is no corresponding increase in mean fluorescence intensity of the IL2r or other lymphocyte activation antigens, in contrast with the upregulation of these antigens on the CD3 stimulated lymphocytes.

It has been suggested that this increased expression of MHC class II antigens without a corresponding increase in other activation antigens could be due to a G1/S stage block in lymphocyte activation in RA,^{17 18} possibly due to deficient IL2 production or high affinity IL2r expression, or both.^{21 22} An alternative explanation for these results, which we consider more likely, is that of prior activation of RA T lymphocytes, especially in intra-articular sites, by an unknown antigen. Several studies have indirectly supported this hypothesis, with the demonstration of 'very late activation' markers on RA synovial fluid²⁷ and synovial tissue²⁶ lymphocytes, and impaired expression of IL2r as well as deficient mitogenic responses to plant lectins, which spontaneously recover when RA peripheral blood lymphocytes are 'rested' in vitro.⁴³ The results presented here from a large group of patients with RA support this theory of prior activation of T lymphocytes in RA with persistent MHC class II antigen expression and downregulation of the CD3 antigen on synovial fluid lymphocytes in the absence of increased expression or upregulation of other early and mid-activation markers (transferrin receptor, 4F2, IL2r). Results presented elsewhere show impairment of mitogenic responses, IL2 production, and IL2r expression by peripheral blood and synovial fluid lymphocytes from this same group of patients,³⁰ similar to those previously described for patients with RA.^{20 21 25} These findings are not unique to patients with RA as similar results (increased MHC class II expression, CD3 and CD4 downregulation, and a larger subpopulation of synovial fluid lymphocytes expressing MHC class II antigens as well as other lymphocyte activation antigens with the exception of IL2r) were seen in the patients with psoriatic arthritis and Reiter's syndrome.

The results from this study suggest, therefore, that similar lymphocyte marker expression on intra-articular T lymphocytes is seen in RA and non-RA inflammatory arthritides. Thus if prior activation of T lymphocytes is the cause of these changes then a similar pathogenic event may be occurring in all inflammatory arthritides, with the initiating antigen(s) and the quantitative response being the only difference between these conditions.

M D Smith was supported by an NH and MRC postgraduate medical research scholarship. This research was supported in

part by grants from the Arthritis Foundation of Australia (national and South Australian branches).

- 1 Veys E M, Hermans P, Goldstein G, Kung P, Schindler J, Van Wauwe J. Determination of T lymphocyte subpopulations by monoclonal antibodies in rheumatoid arthritis. Influence of immunomodulating agents. *Int J Immunopharmacol* 1981; 3: 313-9.
- 2 Burmester G R, Yu D T Y, Irani A M, Kunkel H G, Winchester R J. Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis. *Arthritis Rheum* 1981; 24: 1370-6.
- 3 Fox R I, Fong S, Sabharwal N, Carstens S A, Kung P C, Vaughan J H. Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis. *J Immunol* 1982; 128: 351-4.
- 4 Veys E M, Hermans P, Schindler J, et al. Evaluation of T cell subsets with monoclonal antibodies in patients with rheumatoid arthritis. *J Rheumatol* 1982; 9: 25-9.
- 5 Duke O, Panayi G S, Janossy G, Poulter L W, Tidman N. Analysis of T cell subsets in the peripheral blood and synovial fluid of patients with rheumatoid arthritis by means of monoclonal antibodies. *Ann Rheum Dis* 1983; 42: 357-61.
- 6 Kluin-Nelemans H C, van der Linden J A, Gmelig Meyling F H J, Schuurman H J. HLA-DR positive T lymphocytes in blood and synovial fluid in rheumatoid arthritis. *J Rheumatol* 1984; 11: 272-6.
- 7 Bertouch J V, Roberts-Thomson P J, Brooks P M, Bradley J. Lymphocyte subsets and inflammatory indices in synovial fluid and blood of patients with rheumatoid arthritis. *J Rheumatol* 1984; 11: 754-9.
- 8 Luyten F, Suykens S, Veys E M, et al. Peripheral blood T lymphocyte subpopulations determined by monoclonal antibodies in active rheumatoid arthritis. *J Rheumatol* 1986; 13: 864-9.
- 9 Karlsson-Parra A, Svenson K, Hallgren R, Klareskog L, Forsum U. Peripheral blood T lymphocyte subsets in active rheumatoid arthritis—effects of different therapies on previously untreated patients. *J Rheumatol* 1986; 13: 263-8.
- 10 Goto M, Miyamoto T, Nishioka K, Okumura K. Selective loss of suppressor T cells in rheumatoid arthritis patients: analysis of peripheral blood lymphocytes by 2-dimensional flow cytometry. *J Rheumatol* 1986; 13: 853-7.
- 11 Jahn B, Burmester G R, Gramatzki M, Weseloh G, Stock P, Kalden J R. Intra-articular T lymphocytes in monoarticular and oligoarticular inflammatory joint diseases. *J Rheumatol* 1986; 13: 254-8.
- 12 Duke O, Panayi G S, Janossy G, Poulter L W. An immunohistological analysis of lymphocyte subpopulations and their microenvironment in the synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. *Clin Exp Immunol* 1982; 49: 22-30.
- 13 Meijer C J L M, deGraff-Reitsma C B, Lafeber G J M, Cats A. In situ localisation of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies. *J Rheumatol* 1982; 9: 359-65.
- 14 Young C L, Adamson T C, Vaughan J H, Fox R I. Immunohistologic characterisation of synovial membrane lymphocytes in rheumatoid arthritis. *Arthritis Rheum* 1984; 27: 32-9.
- 15 Burmester G R, Jahn B, Gramatzki M, Zacher J, Kalsen J R. Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. *J Immunol* 1984; 133: 1230-4.
- 16 Salmon M, Bacon P A, Symmons D P M, Blann A D. Transferrin receptor bearing cells in the peripheral blood of patients with rheumatoid arthritis. *Clin Exp Immunol* 1985; 62: 346-52.
- 17 Goto M, Miyamoto T, Nishioka K. 2 dimensional flow cytometric analysis of activation antigens expressed on the synovial fluid T cells in rheumatoid arthritis. *J Rheumatol* 1987; 14: 230-3.
- 18 Pitzalis C, Kingsley G, Lanchbury J S S, Murphy J, Panayi G S. Expression of HLA-DR, DQ and DP antigens and interleukin-2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: Evidence for "frustrated" activation. *J Rheumatol* 1987; 14: 662-6.
- 19 Acuto O, Reinherz E L. The human T cell receptor. *N Engl J Med* 1985; 312: 1100-11.
- 20 Combe B, Pope R M, Fischbach M, Darnell B, Baron S, Talal N. Interleukin 2 in rheumatoid arthritis: production of and response to interleukin 2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. *Clin Exp Immunol* 1985; 59: 520-8.
- 21 Combe B, Andary M, Klein B, Clot J, Sany J. Regulation of interleukin 2 production in rheumatoid arthritis. *J Rheumatol* 1987; 14: 226-9.
- 22 Emery P, Wood N, Gentry K, Stockman A, Mackay I R, Bernard O. High-affinity interleukin-2 receptors on blood lymphocytes are decreased during active rheumatoid arthritis. *Arthritis Rheum* 1988; 31: 1176-81.
- 23 Jahn B, Burmester G R, Stock P, Rohwer P, Kalden J R. Functional and phenotypical characterisation of activated T cells from intra-articular sites in inflammatory joint diseases. Possible modulation of the CD3 antigen. *Scand J Immunol* 1987; 26: 745-54.
- 24 Kitas G D, Salmon M, Farr M, Gaston J S H, Bacon P A. Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications. *Clin Exp Immunol* 1988; 73: 242-9.
- 25 Miyasaka N, Nakamura T, Russel I J, Talal N. Interleukin 2

- deficiencies in rheumatoid arthritis and systemic lupus erythematosus. *Clin Immunol Immunopathol* 1984; **31**: 104–17.
- 26 Cush J J, Lipsky P E. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. *Arthritis Rheum* 1988; **31**: 1230–8.
 - 27 Hemler M E, Glass D, Coblin J S, Jacobson J G. Very late activation antigens on rheumatoid synovial fluid T lymphocytes: association with stages of T cell activation. *J Clin Invest* 1986; **78**: 696–702.
 - 28 Inman R D, Klein M H. Immunological studies of serum and synovial fluid in Reiter's syndrome. *Arthritis Rheum* 1984; **27**: S85.
 - 29 Nordström D, Kontinen Y T, Bergroth V, Leirisalo-Repo M. Synovial fluid cells in Reiter's syndrome. *Ann Rheum Dis* 1985; **44**: 852–6.
 - 30 Smith M D, Roberts-Thomson P J. Interleukin 2 and interleukin 2 inhibitors in human serum and synovial fluid. 2. Mitogenic stimulation, interleukin 2 production and interleukin 2 receptor expression in rheumatoid arthritis, psoriatic arthritis and Reiter's syndrome. *J Rheumatol* 1989; **16**: 897–903.
 - 31 Ropes M W, Bennett G A, Cobb S, Jacox R, Jessar R A. 1958 revision of the diagnostic criteria for rheumatoid arthritis. *Arthritis Rheum* 1959; **2**: 16–20.
 - 32 Wilkens R F, Arnett F C, Bitter T. Reiter's syndrome. Evaluation of preliminary criteria for definite disease. *Arthritis Rheum* 1981; **24**: 844–9.
 - 33 Sowden J A, Roberts-Thomson P J, Zola H. Evaluation of CD5-positive B cells in blood and synovial fluid of patients with rheumatic diseases. *Rheumatol Int* 1987; **7**: 255–9.
 - 34 Brooks D A, Zola H, McNamara P J, et al. Membrane antigens of human cells of the monocyte/macrophage lineage studied with monoclonal antibodies. *Pathology* 1983; **15**: 45–52.
 - 35 Watson A J, DeMars R, Trowbridge I S, Bach F H. Detection of a novel human class II HLA antigen. *Nature* 1983; **304**: 358–61.
 - 36 Beckman I G R, Bradley J, Brooks D, Zola H. Delineation of serologically distinct monomorphic determinants of human MHC class II antigens: evidence of heterogeneity in their topographic distribution. *Mol Immunol* 1983; **21**: 205–14.
 - 37 Zola H, Furness V, Barclay S, et al. The p24 leucocyte membrane antigen: modulation associated with lymphocyte activation and differentiation. *Immunology and Cell Biology* 1989; **67**: 63–70.
 - 38 Haynes B F, Hemler M E, Mann D L, et al. Characterisation of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. *J Immunol* 1981; **126**: 1409–14.
 - 39 Smith K A, Cantrell D A. Interleukin 2 regulates its own receptors. *Proc Natl Acad Sci USA* 1985; **82**: 864–8.
 - 40 Welte K, Andreef M, Platzer E, et al. Interleukin 2 regulates the expression of TAC antigen on peripheral blood T lymphocytes. *J Exp Med* 1984; **160**: 1390–403.
 - 41 Goto M, Miyamoto T, Nishioka K, Uchida S. T cytotoxic and helper cells are markedly increased, and T suppressor and inducer cells are markedly decreased, in rheumatoid synovial fluids. *Arthritis Rheum* 1987; **30**: 737–43.
 - 42 Pincus S H, Clegg D O, Ward J R. Characterization of T cells bearing HLA-DR antigens in rheumatoid arthritis. *Arthritis Rheum* 1985; **28**: 8–15.
 - 43 Plater-Zyberk C, Rockett K A, Maini R N. Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis. *Clin Exp Immunol* 1988; **73**: 93–7.
 - 44 Ruschen S, Lemm G, Warnatz H. Interleukin-2 secretion by synovial fluid lymphocytes in rheumatoid arthritis. *Br J Rheumatol* 1988; **27**: 350–6.
 - 45 Alcover A, Ramarli D, Richardson N E, Chang H C, Reinherz E L. Functional and molecular aspects of human T lymphocytes activation via T3-Ti and T11 pathways. *Immunol Rev* 1987; **95**: 6–35.